REGENXBIO Announces RGX-314 Data Presentation at the American Academy of Ophthalmology 2021 Annual Meeting
Title: Two Year Results from the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of nAMD, and an Update on Suprachoroidal Trials
Session Title: RET10 - Section VIII: First-time Results of Clinical Trials
Date/Time: Friday, November 12, 2021, from
Type: Oral presentation
RGX-314 is being investigated as a potential one-time treatment for wet AMD, diabetic retinopathy, and other chronic retinal conditions. RGX-314 consists of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF). RGX-314 is believed to inhibit the VEGF pathway by which new, leaky blood vessels grow and contribute to the accumulation of fluid in the retina.
About REGENXBIO Inc.
SCS Microinjector® is a trademark of Clearside Biomedical, Inc. All other trademarks referenced herein are registered trademarks of
Investor Relations and Corporate Communications
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-rgx-314-data-presentation-at-the-american-academy-of-ophthalmology-2021-annual-meeting-301417322.html